BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:JANX007 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of JANX007\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05519449-10887@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:JANX007: Phase 1 readout est. (NCT05519449)
DESCRIPTION:JANX007\, phase 1\, Prostate Cancer.\nStudy: Study of JANX007 i
 n Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-P
 SMA-01)\nEstimated primary completion: July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/janx007#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05519449
URL:https://assetmemo.bio/drug/janx007#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07813637-10887@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:JANX007: Phase 1 readout est. (NCT07813637)
DESCRIPTION:JANX007\, phase 1\, Prostate Cancer.\nStudy: Phase 1 Trial to S
 tudy JANX013 and JANX007 Combination in mCRPC\nEstimated primary completio
 n: July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/janx007
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078
 13637
URL:https://assetmemo.bio/drug/janx007#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
